Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (32)
2024
-
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
ESMO Open, Vol. 9, Núm. 9
-
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 13, pp. 2693-2701
2023
-
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer
Clinical Cancer Research, Vol. 29, Núm. 17, pp. 3292-3300
-
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229
-
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60
2022
-
Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer
Journal for immunotherapy of cancer, Vol. 10, Núm. 12
-
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity
The Journal of experimental medicine, Vol. 219, Núm. 12
-
Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness
Frontiers in Cell and Developmental Biology, Vol. 10
-
Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers
ESMO Open, Vol. 7, Núm. 2
-
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Cancer Discovery, Vol. 12, Núm. 5, pp. 1248-1265
2021
-
A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment
Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 434-449
-
Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891
-
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology
ESMO Open
-
Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma
Frontiers in Cell and Developmental Biology, Vol. 9
-
OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors
Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472
2020
-
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 18, Núm. 6, pp. 452-460
-
Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients
Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348
2019
-
Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study
Medical Oncology, Vol. 36, Núm. 3
-
Correction to: SEOM clinical guideline for treatment of kidney cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (47-56), 10.1007/s12094-017-1765-4)
Clinical and Translational Oncology
-
Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” (European Urology (2018) 73(3) (462–468), (S0302283817310151) (10.1016/j.eururo.2017.11.023))
European Urology